Skip to main content
Erschienen in: Molecular Imaging and Biology 1/2020

21.05.2019 | Research Article

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake

verfasst von: Karine Sahakyan, Xin Li, Martin A. Lodge, Rudolf A. Werner, Ralph A. Bundschuh, Lena Bundschuh, Harshad R. Kulkarni, Christiane Schuchardt, Richard P. Baum, Kenneth J. Pienta, Martin G. Pomper, Ashley E. Ross, Michael A. Gorin, Steven P. Rowe

Erschienen in: Molecular Imaging and Biology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging has impacted the management of patients with prostate cancer (PCa) in many parts of the world. PSMA-targeted endoradiotherapies are also being increasingly utilized and for these applications, the radiopharmaceutical distribution in normal organs is particularly important because it may limit the dose that can be delivered to tumors. In this study, we measured both interpatient and intrapatient variability of [18F]DCFPyL uptake in the most relevant normal organs.

Procedures

Baseline and 6-month follow-up PSMA-targeted [18F]DCFPyL PET/computed tomography (CT) scans from 39 patients with PCa were reviewed. Volumes of interest were manually drawn using the best visual approximation of the organ edge for both lacrimal glands, all four major salivary glands, the liver, the spleen, and both kidneys for all patients. The average SUVmean, the COVs, and intraclass correlation coefficients (ICCs) across scans were calculated. Bland-Altman analyses were performed for all organs to derive repeatability coefficients (RCs).

Results

The liver demonstrated the lowest interpatient variability (13.0 and 16.6 % at baseline and follow-up, respectively), while the spleen demonstrated the largest interpatient variability (44.6 and 51.0 % at baseline and follow-up, respectively). The lowest intrapatient variability was found in the spleen (ICC 0.86) while the highest intrapatient variability was in the kidneys (ICCs 0.40–0.50). Bland-Altman analyses showed 95 % repeatability coefficients for mean uptake > 40 % for multiple organs and were highest for the lacrimal glands, kidneys, and spleen.

Conclusions

Normal organs demonstrate significant variability in uptake of the PSMA-targeted radiotracer [18F]DCFPyL. Depending on the organ, different contributions of interpatient and intrapatient factors affect the intrinsic variability. The RCs also vary significantly among the different organs were highest for the lacrimal glands, kidneys, and spleen. These findings may have important implications for the design of clinical protocols and personalized dosimetry for PSMA-targeted endoradiotherapies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY (2016) PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis 19:223–230CrossRef Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY (2016) PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis 19:223–230CrossRef
2.
Zurück zum Zitat Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, Asfhar-Oromieh A, Herrmann K, Eiber M (2017) PSMA ligands for PET imaging of prostate cancer. J Nucl Med 58:1545–1552CrossRef Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, Asfhar-Oromieh A, Herrmann K, Eiber M (2017) PSMA ligands for PET imaging of prostate cancer. J Nucl Med 58:1545–1552CrossRef
3.
Zurück zum Zitat Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N (2016) Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937CrossRef Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N (2016) Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937CrossRef
4.
Zurück zum Zitat Mena E, Lindenberg ML, Shih JH, Adler S, Harmon S, Bergvall E, Citrin D, Dahut W, Ton AT, McKinney Y, Weaver J, Eclarinal P, Forest A, Afari G, Bhattacharyya S, Mease RC, Merino MJ, Pinto P, Wood BJ, Jacobs P, Pomper MG, Choyke PL, Turkbey B (2018) Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging 45:4–11CrossRef Mena E, Lindenberg ML, Shih JH, Adler S, Harmon S, Bergvall E, Citrin D, Dahut W, Ton AT, McKinney Y, Weaver J, Eclarinal P, Forest A, Afari G, Bhattacharyya S, Mease RC, Merino MJ, Pinto P, Wood BJ, Jacobs P, Pomper MG, Choyke PL, Turkbey B (2018) Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging 45:4–11CrossRef
5.
Zurück zum Zitat Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K (2018) Impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 59:434–441CrossRef Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K (2018) Impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 59:434–441CrossRef
6.
Zurück zum Zitat Han S, Woo S, Kim YJ, Suh CH (2018) Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 74:179–190CrossRef Han S, Woo S, Kim YJ, Suh CH (2018) Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 74:179–190CrossRef
7.
Zurück zum Zitat Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ (2015) 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56:1169–1176CrossRef Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ (2015) 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56:1169–1176CrossRef
8.
Zurück zum Zitat Kabasakal L, AbuQbeitah M, Aygun A et al (2015) Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 42:1976–1983CrossRef Kabasakal L, AbuQbeitah M, Aygun A et al (2015) Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 42:1976–1983CrossRef
9.
Zurück zum Zitat Kulkarni HR, Singh A, Langbein T et al (2018) Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. Br J Radiol 20180308 Kulkarni HR, Singh A, Langbein T et al (2018) Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. Br J Radiol 20180308
10.
Zurück zum Zitat Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SCrossRef Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SCrossRef
11.
Zurück zum Zitat Li X, Rowe SP, Leal JP, Gorin MA, Allaf ME, Ross AE, Pienta KJ, Lodge MA, Pomper MG (2017) Semiquantitative parameters in PSMA-targeted PET imaging with 18F-DCFPyL: variability in normal-organ uptake. J Nucl Med 58:942–946CrossRef Li X, Rowe SP, Leal JP, Gorin MA, Allaf ME, Ross AE, Pienta KJ, Lodge MA, Pomper MG (2017) Semiquantitative parameters in PSMA-targeted PET imaging with 18F-DCFPyL: variability in normal-organ uptake. J Nucl Med 58:942–946CrossRef
12.
Zurück zum Zitat Wondergem M, van der Zant FM, Vlottes PW, Knol RJJ (2018) Effects of fasting on 18F-DCFPyL uptake in prostate cancer lesions and tissues with known high physiologic uptake. J Nucl Med 59:1081–1084CrossRef Wondergem M, van der Zant FM, Vlottes PW, Knol RJJ (2018) Effects of fasting on 18F-DCFPyL uptake in prostate cancer lesions and tissues with known high physiologic uptake. J Nucl Med 59:1081–1084CrossRef
13.
Zurück zum Zitat Ravert HT, Holt DP, Chen Y, Mease RC, Fan H, Pomper MG, Dannals RF (2016) An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL. J Label Comp Radiopharm 59:439–450CrossRef Ravert HT, Holt DP, Chen Y, Mease RC, Fan H, Pomper MG, Dannals RF (2016) An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL. J Label Comp Radiopharm 59:439–450CrossRef
14.
Zurück zum Zitat Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG (2011) 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17:7645–7653CrossRef Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG (2011) 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17:7645–7653CrossRef
15.
Zurück zum Zitat Rowe SP, Vicente E, Anizan N, Wang H, Leal JP, Lodge MA, Frey EC, Wahl RL (2015) Repeatability of radiotracer uptake in normal abdominal organs with 111In-pentetreotide quantitative SPECT/CT. J Nucl Med 56:985–988CrossRef Rowe SP, Vicente E, Anizan N, Wang H, Leal JP, Lodge MA, Frey EC, Wahl RL (2015) Repeatability of radiotracer uptake in normal abdominal organs with 111In-pentetreotide quantitative SPECT/CT. J Nucl Med 56:985–988CrossRef
16.
Zurück zum Zitat Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86:420–428CrossRef Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86:420–428CrossRef
17.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef
18.
Zurück zum Zitat Heijmen L, de Geus-Oei LF, de Wilt JH et al (2012) Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. Eur J Nucl Med Mol Imaging 39:1858–1867CrossRef Heijmen L, de Geus-Oei LF, de Wilt JH et al (2012) Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. Eur J Nucl Med Mol Imaging 39:1858–1867CrossRef
19.
Zurück zum Zitat Lodge MA (2017) Repeatability of SUV in oncologic 18F-FDG PET. J Nucl Med 58:523–532CrossRef Lodge MA (2017) Repeatability of SUV in oncologic 18F-FDG PET. J Nucl Med 58:523–532CrossRef
20.
Zurück zum Zitat Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, Gatenby RA, Gillies RJ, Eikman EA (2013) Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med 38:175–182CrossRef Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, Gatenby RA, Gillies RJ, Eikman EA (2013) Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med 38:175–182CrossRef
21.
Zurück zum Zitat Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Govindan R, Torigian DA, Karp JS, Yu JQ, Subramaniam RM, Halvorsen RA, Siegel BA, ACRIN 6678 Research team, MK-0646-008 Research team (2015) Repeatability of 18F-FDG PET/CT in advanced non-small cell lung cancer: prospective assessment in 2 multicenter trials. J Nucl Med 56:1137–1143CrossRef Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Govindan R, Torigian DA, Karp JS, Yu JQ, Subramaniam RM, Halvorsen RA, Siegel BA, ACRIN 6678 Research team, MK-0646-008 Research team (2015) Repeatability of 18F-FDG PET/CT in advanced non-small cell lung cancer: prospective assessment in 2 multicenter trials. J Nucl Med 56:1137–1143CrossRef
22.
Zurück zum Zitat Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathologic validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678–688CrossRef Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathologic validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678–688CrossRef
Metadaten
Titel
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake
verfasst von
Karine Sahakyan
Xin Li
Martin A. Lodge
Rudolf A. Werner
Ralph A. Bundschuh
Lena Bundschuh
Harshad R. Kulkarni
Christiane Schuchardt
Richard P. Baum
Kenneth J. Pienta
Martin G. Pomper
Ashley E. Ross
Michael A. Gorin
Steven P. Rowe
Publikationsdatum
21.05.2019
Verlag
Springer International Publishing
Erschienen in
Molecular Imaging and Biology / Ausgabe 1/2020
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-019-01376-9

Weitere Artikel der Ausgabe 1/2020

Molecular Imaging and Biology 1/2020 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.